Back to top

Image: Bigstock

Is Biogen Inc. (BIIB) a Great Stock for Value Investors?

Read MoreHide Full Article

Value investing is easily one of the most popular ways to find great stocks in any market environment. After all, who wouldn’t want to find stocks that are either flying under the radar and are compelling buys, or offer up tantalizing discounts when compared to fair value?

One way to find these companies is by looking at several key metrics and financial ratios, many of which are crucial in the value stock selection process. Let’s put Biogen Inc.(BIIB - Free Report) stock into this equation and find out if it is a good choice for value-oriented investors right now, or if investors subscribing to this methodology should look elsewhere for top picks:

PE Ratio

A key metric that value investors always look at is the Price to Earnings Ratio, or PE for short. This shows us how much investors are willing to pay for each dollar of earnings in a given stock, and is easily one of the most popular financial ratios in the world. The best use of the PE ratio is to compare the stock’s current PE ratio with: a) where this ratio has been in the past; b) how it compares to the average for the industry/sector; and c) how it compares to the market as a whole.

On this front, Biogen has a trailing twelve months PE ratio of 15.6, as you can see in the chart below:


 

This level actually compares pretty favorably with the market at large, as the PE for the S&P 500 stands at about 20.3. If we focus on the long-term PE trend, Biogen’s current PE level puts below its midpoint of 23.3 over the past five years. Moreover, the current level stands way below the highs for the stock, indicating that it could be a solid entry point.
 


Further, the stock’s PE also compares favorably with the industry’s trailing twelve months PE ratio, which stands at 38.8. At the very least, this indicates that the stock is relatively undervalued right now, compared to its peers.
 


We should also point out that Biogen has a forward PE ratio (price relative to this year’s earnings) of just 14.7, so it is fair to say that a slightly more value-oriented path may be ahead for Apple stock in the near term too.

PEG Ratio


While earnings are certainly important, it is essential to know how much you are paying for the growth of earnings as well. One can easily do that with the PEG ratio (ratio of the P/E to the expected future earnings growth rate). The PEG ratio gives a more complete picture of the valuation of a stock than the P/E ratio.

Biogen’s PEG ratio stands at just 1.9, compared with the industry average of 3.3. This suggests a decent undervalued trading relative to its earnings growth potential right now.



Broad Value Outlook

In aggregate, Biogen currently has a Zacks Value Style Score of B, putting it into the top 40% of all stocks we cover from this look. This makes Biogen a solid choice for value investors, and some of its other key metrics make this pretty clear too.

For example, P/CF ratio (another great indicator of value) comes in at 13.5, which is far better than the industry average of 23.8. Clearly, BIIB is a solid choice on the value front from multiple angles.

What About the Stock Overall?


While Biogen might be a good choice for value investors, there are plenty of other factors to consider before investing in this name. In particular, it is worth noting that the company has a Growth grade of D and a Momentum score of A. This gives BIIB a Zacks VGM score—or its overarching fundamental grade—of B. (You can read more about the Zacks Style Scores here >>)

The current quarter has seen thirteen upward estimate revisions in the past sixty days compared to three downward, while the full year estimate has seen sixteen upward and three downward revisions in the same time frame.

As a result, the current quarter consensus estimate has increased 0.2% in the past two months, while the full year estimate has risen by 0.1%. You can see the consensus estimate trend and recent price action for the stock in the chart below:

Biogen Inc. Price and Consensus

The stock holds a Zacks Rank #3 (Hold), which indicates expectations of in-line performance from the company in the near term. However, Biogen is enjoying bullish analyst sentiment, as indicated by the positive estimate revisions, and this works in the company’s favor.

Bottom Line

Biogen is an inspired choice for value investors, as it is hard to beat its incredible lineup of statistics on this front. Despite having a Zacks Rank #3, the stock belongs to an industry which is ranked among the Top 40%, which indicates that broader factors are favorable for the company.

So, despite a Zacks Rank #3, we believe that bullish analyst sentiment and favorable industry factors make this value stock a compelling pick.

Looking for Stocks with Skyrocketing Upside?

Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.  

Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look.   

See the pot trades we're targeting>>


Unique Zacks Analysis of Your Chosen Ticker


Pick one free report - opportunity may be withdrawn at any time


Biogen Inc. (BIIB) - $25 value - yours FREE >>

Published in